key: cord-0970521-bgwndx82 authors: Prochazka, Mateo; Charles, Hannah; Allen, Hester; Cole, Michelle; Hughes, Gwenda; Sinka, Katy title: Rapid Increase in Lymphogranuloma Venereum among HIV-Negative Men Who Have Sex with Men, England, 2019 date: 2021-10-03 journal: Emerg Infect Dis DOI: 10.3201/eid2710.210309 sha: fd2ed8c6e9c42def9e9c09a61f673f04c7f97bac doc_id: 970521 cord_uid: bgwndx82 Incidence of lymphogranuloma venereum increased in England during 2018–2019, after a period of decline. Our retrospective analysis of national surveillance data identified a rapid increase in diagnoses among HIV-negative men who have sex with men. These findings indicate a need for sustained surveillance and targeted public health action. We conducted a retrospective analysis of adult (>16 years of age) MSM in England who visited sexual health service (SHS) sites during January 1, 2015-December 31, 2019. We obtained data from the Genitourinary Medicine Clinic Activity Dataset Sexually Transmitted Infection (STI) Surveillance System, which has recorded LGV diagnoses, obtained through multiplex reverse transcription PCR (4), since 2011. We included all SHS site visits by men who self-reported as MSM in England during 2015-2019. We cleaned and deduplicated data according to a routine practice described previously (11). We described the number of annual LGV diagnoses during 2015-2019 by age group, race (White [e.g., White British, White Irish, or White other background] and non-White), place of residence (London or rest of England), region of birth (United Kingdom, Europe, Asia, Oceania, Latin America and the Caribbean [LAC], North America, and Africa), history of a bacterial STI in the previous year (defi ned as having a recorded diagnoses of chlamydia, gonorrhea, or syphilis in the 365 days before attendance), and HIV status at time of LGV diagnosis. We used quarterly data on LGV diagnoses stratifi ed by HIV status to examine changes over time in the proportion of diagnoses that were made among MSM who are HIV-negative or with unknown HIV status. We used generalized linear models with logarithmic function, Poisson distribution, and robust variances to identify the changes in risk for LGV in 2019 by quarter. We included covariates in the model if they showed strong association with an LGV diagnosis in the bivariate analyses (p<0.05). We adjusted the fi nal model for HIV status, history of a previous bacterial STI, region of birth, and age group. We performed all data analyses using Stata 15.1 (https://www.stata.com). Public Health England collects pseudonymized, electronic data on all STI tests and diagnoses from all commissioned SHS sites in England (11). Public Health England has approval to handle data obtained by the Genitourinary Medicine Clinic Activity Dataset STI Surveillance System under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002 (https://www.gov.uk/government/ publications/hiv-and-sti-data-sharing-policy). Of 2,116,345 SHS visits by MSM during 2015-2019, we identified 3,461 diagnoses of LGV (Table 1) . The highest number of LGV diagnoses was recorded in 2019 (n = 1,018); this increase was mainly attributed to increases in diagnoses in the third and fourth quarter of the year ( Figure 1 ). The proportion of diagnoses among MSM who are HIV-negative or with unknown HIV status increased from 31.4% in 2015 to 58.4% in 2019 (Table 1 ). In 2019, most LGV diagnoses in MSM were among White MSM (72.7%) and MSM residing in London (79.1%). A total of 614 (60.3%) LGV diagnoses in 2019 were made among those who had a bacterial STI diagnosis in the previous year (Table 1) . Our regression analyses included 526,102 visits and 1,018 LGV diagnoses among MSM in England in 2019 (Table 2) . Compared with quarter 1 of 2019, the risk for having LGV diagnosed was 73% higher in quarter 3 and 66% higher in quarter 4. Living with HIV, residing in London, and having a previous bacterial STI were strongly associated with an LGV diagnosis in the crude and adjusted models ( Table 2) . Being born in LAC or in Europe outside of the UK were also associated with increased risk for LGV ( Figure 2 ). We show that a rapid increase occurred in LGV diagnoses in England in 2019, particularly affecting MSM who are HIV-negative or with unknown HIV status, such that nearly 60% of all LGV diagnoses are now in this group. This trend represents a major shift in the epidemiology of LGV; infection was previously associated with MSM living with HIV (2). However, having LGV diagnosed continues to be associated with living with HIV, as well as having a previous STI diagnosis, residing in London, and being born in LAC or Europe outside the United Kingdom. An earlier decline in LGV diagnoses (9) has been attributed to revisions to LGV testing guidelines that led to expanded testing (5, 12) . However, because no revisions have been made since 2015, changes to testing practice are unlikely to explain the recent increase, which is concurrent with increases in test positivity (10) . Of note, use of HIV preexposure prophylaxis (PrEP) in England may have contributed to increased association with previous STI diagnosis further supports this hypothesis. Further investigation will be needed to understand the impact of HIV prevention on transmission of bacterial STIs. However, the increasing proportion of LGV diagnoses among HIVnegative MSM during 2017-2019 is in line with reports from other countries in Europe (6, 8, 14, 15) . The first limitation of this study is that unmeasured behavioral covariates (e.g., number of partners, PrEP use, drug use, group sex, and venuebased activities) were not available. Inclusion of behavioral covariates in routine STI surveillance in England is underway and will be examined in future iterations of these analyses. Second, the risk among some groups, such as those not born in the United Kingdom, could be overestimated because of differing patterns of healthcare access and barriers to access. In summary, we report a steep increase in the number of LGV diagnoses identified in SHS sites after a period of decline, which indicates the need for sustained surveillance and public health action. Our findings indicate that the epidemiology of LGV has changed, and an increased number of diagnoses are occurring among MSM who are HIV-negative or with unknown HIV status, highlighting the need to integrate health promotion and increase LGV testing within HIV prevention delivery. In addition, increased LGV risk among MSM born in LAC and in countries in Europe that are outside the United Kingdom indicates the need for increased accessibility of health promotion materials and wider engagement with these communities. Dr. Prochazka is a medical doctor and epidemiologist focused on control of infectious diseases. He is a consultant epidemiology scientist supporting STI and COVID-19 surveillance at Public Health England. Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 10, October 2021 Rapid increase in lymphogranuloma venereum in men who have sex with men LGV Incident Group. Lymphogranuloma venereum diagnoses among men who have sex with men in the U.K.: interpreting a cross-sectional study using an epidemic phase-specific framework Asymptomatic lymphogranuloma venereum in men who have sex with men, United Kingdom Substantial underdiagnosis of lymphogranuloma venereum in men who have sex with men in Europe: preliminary findings from a multicentre surveillance pilot UK national guideline for the management of infection with Chlamydia trachomatis Increasing trends of lymphogranuloma venereum among HIV-negative and asymptomatic men who have sex with men, the Netherlands Prevalence of lymphogranuloma venereum among anorectal Chlamydia trachomatis-positive MSM using pre-exposure prophylaxis for HIV Lymphogranuloma venereum is on the rise in Belgium among HIV negative men who have sex with men: surveillance data from 2011 until the end of Investigating the decline in lymphogranuloma venereum diagnoses in men who have sex with men in the United Kingdom since 2016: an analysis of surveillance data Public Health England. GUMCAD STI Surveillance System: data specifi cation and technical guidance British Association for Sexual Health and HIV. 2013 UK national guideline for the management of lymphogranuloma venereum The context of sexual risk behaviour among men who have sex with men seeking PrEP, and the impact of PrEP on sexual behaviour Lymphogranuloma venereum genovariants in men having sex with men in Italy The silent epidemic of lymphogranuloma venereum inside the COVID-19 pandemic in Unidentifi ed cyst-forming sporozoon causing encephalomyelitis and myositis in dogs Review of Neospora caninum and neosporosis in animals Detection of immunoglobulin G antibodies to Neospora caninum in humans: high seropositivity rates in patients who are infected by human immunodefi ciency virus or have neurological disorders From the neo-(Latin, "new") + spora (Greek, "seed") and canis (Latin, "dog"), Neospora caninum is a sporozoan parasite that was fi rst described in 1984. It is a major pathogen of cattle and dogs but can also infect horses, goats, sheep, and deer. Antibodies to N. caninum have been found in humans, predominantly in those with HIV infection, although the role of this parasite in causing or exacerbating illness is unclear.